Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03514420 · ClinicalTrials.gov registry record · Phase 2
Study of AKCEA-ANGPTL3-LRx (ISIS 703802) in Participants With Familial Partial Lipodystrophy (FPL)
A Phase 2 study, sponsored by Akcea Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 4
- Enrollment target
NCT03514420: Completed Phase 2 study, sponsored by Akcea Therapeutics.
NCT03514420 is a Phase 2 study that has completed, run by Akcea Therapeutics. The registered enrollment target is 4 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03514420, a Phase 2 study, has completed, sponsored by Akcea Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 4 participants
- Enrollment target
Study Summary
This is a single-center, open-label study to evaluate the efficacy of AKCEA-ANGPTL3-LRx for reduction of fasting triglycerides in participants with familial partial lipodystrophy.
Primary Outcome
The baseline was defined as the average of Day 1 pre-dose fasting assessment and the last fasting measurement prior to Day 1 pre-dose fasting assessment.
Interventions
- DRUG AKCEA-ANGPTL3-LRx
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2018-06-15 |
| Est. Completion | 2019-08-21 |
| Phase | Phase 2 |
What the finished NCT03514420 record still lists
NCT03514420 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 4 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 1 intervention - of which AKCEA-ANGPTL3-LRx is the first listed.
NCT03514420 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03514420 about?
NCT03514420 is a clinical study titled "Study of AKCEA-ANGPTL3-LRx (ISIS 703802) in Participants With Familial Partial Lipodystrophy (FPL)". This is a single-center, open-label study to evaluate the efficacy of AKCEA-ANGPTL3-LRx for reduction of fasting triglycerides in participants with familial partial lipodystrophy.
What is the current status of trial NCT03514420?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 4 participants. The study started on 2018-06-15. Estimated completion is 2019-08-21.
What interventions are being tested in trial NCT03514420?
The interventions under investigation include: AKCEA-ANGPTL3-LRx (DRUG).
Who is sponsoring clinical trial NCT03514420?
This trial is sponsored by Akcea Therapeutics, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03514420's enrollment target sits among peer trials
4 2001st of 2000 the lowest of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI